BALTIMORE, Aug. 14, 2012 /PRNewswire/ -- BD Diagnostics, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), today announced that the new BD MAX™ MRSA molecular test has received a Moderate ...
BAGNEUX, France--(BUSINESS WIRE)--Regulatory News: Genomic Vision (FR0011799907 – GV – the “Company”), a Euronext-listed biotechnology company that develops products and services for the highly ...
STEMart, a US-based provider of comprehensive services for all phases of medical device development, has announced the availability of its robust In Vitro Micronucleus Test service to meet the ...
INDIANAPOLIS, Dec. 5, 2011 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has filed a 510(k) submission to the U.S. Food and Drug Administration (FDA) for a fully automated ...
ANGLE PLC chief executive Andrew Newland joins Proactive's Stephen Gunnion with details of a supplier agreement with AstraZeneca PLC to develop an androgen receptor (AR) detection assay to enhance ...
IRVING, Texas, and OSAKA, Japan, Oct. 14, 2021 /PRNewswire/ -- Caris Life Sciences®, a molecular science company developing and delivering technologies to revolutionize healthcare, and Ono ...
Learn how a custom ADA assay was designed, incorporating acid dissociation with the ACE method to overcome drug interference using other standardized formats. Get the essential updates shaping the ...
CALGARY, AB, July 9, 2025 /PRNewswire/ - Nanalysis Scientific Corp. (NSCI:CA) ("the Company", TSXV: NSCI, OTCQX: NSCIF, FRA: 1N1), a leader in portable NMR instruments and MRI technology for ...
* SQI Diagnostics Inc - signed a revenue-producing agreement with a pharmaceutical co to provide assay development as well as sample testing services Source text for Eikon: Further company coverage: ...
The "Global Oxidative Stress Assay Market for Pharmaceutical Industry 2018-2022" report has been added to ResearchAndMarkets.com's offering. The global oxidative stress assay market for pharmaceutical ...
(RTTNews) - Acumen Pharmaceuticals (ABOS), Monday reported that using a plasma pTau217 screening assay in its Phase?2 ALTITUDE-AD study of sabirnetug reduced trial screening costs by about 40 percent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results